2007: SLE: Clinical Aspects and Treatment I
Search or Browse by Day

SLE: Clinical Aspects and Treatment I

426
Progressive Normalization of Autoantibody, Immunoglobulin, and Complement Levels Over 2.5 Years of Belimumab (Fully Human Monoclonal Antibody to BLyS) Therapy in Systemic Lupus Erythematosus (SLE) Patients
427
Safety Profile of Belimumab (Fully Human Monoclonal Antibody to BLyS) in Patients with Systemic Lupus Erythematosus (SLE) Treated During a Placebo-Controlled Trial and in a Long-Term Continuation Study
428
Safety of MEDI-545, an Anti-Interferon-α Monoclonal Antibody, in MI-CP126, a Phase 1 Study in Systemic Lupus Erythematosus (SLE)
429
Neutralization of Type I IFN Inducible Genes in Phase I Trial of Anti-IFNα mAb for the Treatment of SLE: Utility as Pharmacodynamic Markers
430
Direct Quantitation of Interferon-Related Transcripts in Whole Blood of SLE Patients Without RNA Isolation and Reverse Transcriptase Real-Time PCR Using Panomics QuantiGene®Plex Technology: Applications in a Phase I Clinical Trial
431
Efficacy, Toxicity and Tolerability of Mycophenolate Mofetil in Patients with Lupus Nephritis, Based on Dose/Weight Ratio
432
Pharmacokinetic Study and Development of a Simple Sampling Strategy to Assess Mycophenolate Mofetil Exposure in Systemic Lupus Erythematosus
433
Treatment of Active Sle-Associated Glomerulonephritis (gn) with the Innovative Immunosuppressant 15-deoxyspergualin (dsg; Gusperimus)
434
Efficacy and Favourable Safety Profile of Short-Term Open Label Infliximab for SLE, but Severe Adverse Events Under Long-Term TNF Blockade
435
Dose Dependent Reduction in Anti-dsDNA Antibody Levels Observed in the Abetimus LJP 394-90-14 Phase 3 Trial
436
Levels Of Urine CXCL16,MCP-1 And Serum sTNFR1 Correlate With Renal Disease Activity in SLE
437
Reliability of Shorter than 24-hr Timed Urine Collections in Estimating 24-hr Total Urine Protein Excretion in Patients with Lupus Nephritis
438
Urine Osteoprotegrin (OPG) in Lupus Nephritis (LN)
439
Urine Monocyte Chemoattractant Protein-1 (MCP-1) in Lupus Nephritis (LN)
440
High Dose Cyclophosphamide Versus Traditional Regimen in Lupus Nephritis (LN)
441
Rituximab in the Treatment of Resistant Systemic Lupus Erythematosus: Failure of Therapy in Rapidly Progressive Crescentic Lupus Nephritis
442
Expression of Endothelial Protein C Receptor (EPCR) in Peritubular Capillaries (PTC) of Renal Cortex Reflects Thwarted Cytoprotection and Associates with Progression of Disease in Lupus Nephritis
443
The Prognostic and Pathogenetic Significance of Severe Focal Segmental Lupus Glomerulonephritis
444
Risk and Predictors of Arterial Thromboembolism in Lupus and Non-Lupus Primary Glomerulonephritis: A Comparative Study
445
N-Terminal Pro-Brain Natriuretic Peptide in Systemic Lupus Erythematosus: Relationship with Inflammation and Cardiovascular Risk Factors
446
Accelerated Atherosclerosis in Women with SLE and Pro-Inflammatory HDL May be Explained in Part by Reduced ApoJ Activity
447
The Relationship of Asymmetric Dimethylarginine and Homocysteine with Arterial Stiffness in SLE and RA patients
448
High-Sensitivity C-Reactive Protein as a Predictor of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus: A Case-Control Study
449
Predictors of Progression in Atherosclerosis over Two Years in SLE
450
The Association between Reference Laboratory Values and the Classification of SLE
451
Diagnostic Value of Transthoracic Compared With Transesophageal Echocardiography for Detection of Libman-Sacks Vegetations
452
Transverse Versus Longitudinal Myeltis in SLE
453
Frequency of and Risk Factors for Incident Ischemic Stroke in Systemic Lupus Erythematosus (SLE)
454
Aspirin Therapy in Conjunction with Selective Serotonin Reuptake Inhibitors (SSRI) for the Treatment of Major Depression in Systemic Lupus Erythematosus
455
The Neurometabolism of Neuropsychiatric Systemic Lupus Erythematosus: Pre-Mortem MR Spectroscopy Paired with Post-Mortem Brain Histopathology
492
Relationship between Memory Impairment and Abnormal Hippocampal Neurometabolites in Patients with SLE
493
Hydroxychloroquine Protects Lupus Patients from Developing Seizures: Data from a Large Multiethnic Cohort
494
Impact of a Common Polymorphism in Platelet Protein gpIIb on Immune Thrombocytopenia and Neurologic Manifestations of Patients with SLE
495
Anti-U1RNP Antibodies in Cerebrospinal Fluid are Associated with Active Central Nervous System Involvements in Patients with Systemic Lupus Erythematosus and Mixed Connective Tissue Disease
496
Serum Perforin, A Novel Apoptosis Marker, Was Increased in Patients with Systemic Lupus Erythematosus (SLE) and it May Have Different Clinical Significance in SLE from Serum Granzyme B
497
April: A Predictive Factor of Response to Treatment in Systemic Lupus Erythematosus?
498
April: A Protective Factor in Systemic Lupus Erythematosus?
499
Haplotypes of IRF5 and Sle: Associations with Disease Features and Sequelae
500
Reactivity of Antibodies to Cyclic Citrullinated Peptide (CCP) and Unmodified Arginine Peptide in SLE as a Marker of Destructive/Deforming Arthritis
501
SLE Patients from Multiplex and Simplex Families in a Large Multi-ethnic Cohort Have Similar Clinical Profiles
502
Work Disability in Systemic Lupus Erythematosus
503
Systemic Lupus Erythematosus (SLE) Patients with Renal Damage Incur Higher Health Care Costs
504
Cost of Illness: Systemic Lupus Erythematosus Versus Lupus Nephritis
505
The Georgia Lupus Registry: Accuracy of Hospital Discharge Data in Identifying Systemic Lupus Erythematosus
506
The Georgia Lupus Registry: Predictors of Capturing SLE Utilizing Hospital Discharge Data
507
Numerical Scoring for Classic BILAG Index
508
BILAG-2004 Index for Assessment of SLE Disease Activity Is Sensitive to Change
509
SLEDAI-2000 Index Does Not Capture SLE Disease Activity Requiring Increase in Therapy as well as BILAG-2004 Index
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>